James E. Flynn 13D and 13G filings for Prelude Therapeutics Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-13 08:58 am Sale | 2024-12-31 | 13G | Prelude Therapeutics Incorporated PRLD | James E. Flynn | 0 0.000% | -4,133,000 (Position Closed) | Filing |
| 2024-02-12 5:30 pm Purchase | 2023-12-31 | 13G | Prelude Therapeutics Incorporated PRLD | James E. Flynn | 4,133,000 9.850% | 910,310 (+28.25%) | Filing |
| 2023-11-13 08:30 am Purchase | 2023-11-02 | 13G | Prelude Therapeutics Incorporated PRLD | James E. Flynn | 3,222,690 7.680% | 3,222,690 (New Position) | Filing |